Date: March 08, 2012
Alameda, California — Abbott (NYSE: ABT) today announced that it has received U.S. Food and Drug Administration (FDA) clearance for the FreeStyle InsuLinx Blood Glucose Monitoring System,[i] the first from Abbott to include a touch-screen interface, automated logbook and several personalization features designed to improve the diabetes management experience for patients. This unique device is also equipped with built-in FreeStyle Auto-Assist software that enables patients to track progress, analyze trends and easily display data for their health care providers. The FreeStyle InsuLinx System will be available to U.S. consumers within the coming months.
According to the American Diabetes Association (ADA), approximately 25.8 million people in the United States have diabetes,[ii] and of those, many require insulin to manage their condition. The FreeStyle InsuLinx System is the newest addition to Abbott’s portfolio of glucose monitoring systems and is designed to use FreeStyle technology to help insulin-using patients monitor their blood glucose levels to allow them to more effectively manage their condition. Specifically, the FreeStyle InsuLinx System offers:
The new FreeStyle InsuLinx blood glucose monitor includes an automated logbook, easy-to-use touch screen and personalization features.
The FreeStyle InsuLinx System is compatible with the FreeStyle InsuLinx blood glucose test strips.
"The new FreeStyle InsuLinx System represents Abbott’s latest advancement in delivering innovative products for people with diabetes who use insulin," said Heather L. Mason, senior vice president, Abbott Diabetes Care. "The improved functionality, data sharing tools and personalization features are designed to improve the diabetes management experience for patients. We are excited to make this product available to diabetes patients in the United States."
Abbott Diabetes Care, based in Alameda, California, is a leader in developing, manufacturing and marketing glucose monitoring systems designed to help people better manage their diabetes. Additional information about Abbott Diabetes Care may be found at www.abbottdiabetescare.com.
Abbott (NYSE: ABT) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionally, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.
[i] FreeStyle and related brand marks are trademarks of Abbott Diabetes Care Inc. in various jurisdictions.
[ii] American Diabetes Association: http://www.diabetes.org/diabetes-basics/diabetes-statistics/
Recent headlines about cinnamon are the result of an accidental finding in a Maryland USDA research center. Incredibly, the catalyst was as American as good old apple pie, flavored with -- what else -- cinnamon. Scientists were testing the effects of various foods on blood sugar (glucose) levels. They expected the classic pie to have an adverse effect, but instead they found it actually helped lower blood glucose levels.
The researchers then took their surprising discovery and tested it in a small 60 patient study conducted in Pakistan, reporting in the journal Diabetes Care. All the patients had been treated for type 2, adult onset diabetes for several years and were taking anti-diabetic drugs to increase their insulin output. But they were not yet taking insulin to help process their blood glucose. The subjects were given small doses of cinnamon ranging from as little as a quarter teaspoon to less than 2 teaspoons a day for 40 days.
February 2012: Confessions of a "Fat Chef":
A candid interview with Chef Jen, a contestent from the new Food Network show, Fat Chef.
January 2012: I Don’t Know Why I Can’t Lose:
Weight Tips to overcome the top five obstacles that prevent weight loss success.
October 2011: Are You Protein Deficient?
Lots of people trying to eat healthy don’t get enough of this crucial nutrientust
2011 Top 5 Diet Mistakes:
How to avoid common problems of popular diet plans.